Epigenetic marker for the identification of il17 positive t cells in complex samples
AssigneeEpiontis GmbH
InventorsSven Olek, Udo Baron
Life of this patent
Estimating the term…
Loading patent…
AssigneeEpiontis GmbH
InventorsSven Olek, Udo Baron
Estimating the term…
The present invention relates to a method, in particular an in vitro method for identifying IL-17 expressing T cells in a blood and/or tissue sample derived from a mammal, comprising analysing the methylation status of at least one CpG position in the gene IL-17A, wherein a demethylation of said at least one CpG position in said sample when compared to an analogous position in a non IL-17 blood cell is indicative for a IL-17 positive CD4 positive T cell. The analyses according to the invention can identify IL-17 positive T cells and distinguish them from all other cells in complex samples, such as, for example, other blood cells. The present invention furthermore provides an improved method for quantifying IL-17 positive T cells in complex samples based on a comparison of the IL-17A methylation with a methylation of at least one marker selected from the group of CD3, FOXP3, and/or GAPDH. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue.
A method for identifying IL-17 positive CD4 positive T cells in a blood and/or tissue sample derived from a mammal, comprising analysing the methylation status of at least one CpG position in gene IL-17A, wherein a demethylation of said at least one CpG position in said sample when compared to an analogous position in a non IL-17 blood cell is indicative for an IL-17 positive CD4 positive T cell.
(canceled)
A primer or a primer pair selected from SEQ ID NO:
Dependencies are inferred from the claim text.